What Clinicians Want to Know: Addressing Community Oncologists’ Questions About the Current and Future Management of Endometrial Cancer

Faculty

Faculty

Floor J Backes

MD

The Ohio State University College of Medicine, The James Cancer Hospital and Solove Research Institute, Columbus, Ohio

Professor, Larry J Copeland Professorship in Gynecologic Oncology, Director of Clinical Research, Associate Fellowship Director, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology

Faculty

Brian M Slomovitz

MD

Mount Sinai Medical Center Miami, Florida

Professor, OB-GYN Florida International University Director, Gynecologic Oncology Co-Chair, Cancer Research Committee

Moderator

Shannon N Westin

MD, MPH, FASCO, FACOG

The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Medical Director, Gynecologic Oncology Center, Director, Early Drug Development, Department of Gynecologic Oncology and Reproductive Medicine

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 8:30 PM — Educational Meeting

MODULE 1: Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC)

• Histologic subtypes and major molecular subgroups of EC; implications for prognosis and therapeutic decision-making
• Optimal approaches to biomarker testing for patients with newly diagnosed advanced EC; implications of biomarker status for treatment decision-making
• Similarities and differences in the designs and enrolled populations of the Phase III RUBY, NRG-GY018 and DUO-E trials evaluating the addition of dostarlimab, pembrolizumab and durvalumab, respectively, to platinum-based chemotherapy as first-line treatment for advanced or recurrent EC
• Published efficacy and safety outcomes from the RUBY, NRG-GY018 and DUO-E trials
• Antitumor activity observed with chemotherapy in combination with dostarlimab, pembrolizumab and durvalumab, respectively, in various patient subgroups —based on microsatellite instability (MSI)/mismatch repair (MMR) status, HER2 status, molecular subtype, et cetera — in the RUBY, NRG-GY018 and DUO-E trials
• FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MMR status; optimal incorporation into up-front therapy
• Ongoing Phase III studies, such as DOMENICA and KEYNOTE-C93, evaluating first-line anti-PD-1/PD-L1 inhibitor monotherapy for MSI-high /MMR-deficient advanced or recurrent EC

MODULE 2: Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC

• Rationale for the evaluation of PARP inhibition for advanced EC; possible therapeutic synergy between anti-PD-1/PD-L1 antibodies and PARP inhibitors
• Key efficacy and safety findings from the Phase III RUBY Part 2 and DUO-E trials evaluating first-line chemoimmunotherapy followed by maintenance anti-PD-1/PD-L1 antibody with a PARP inhibitor for newly diagnosed advanced or recurrent EC
• Outcomes with PARP inhibitors in various patient subsets of the RUBY Part 2 and DUO-E studies
• Potential patient selection for and role of anti-PD-1/PD-L1 antibody/PARP inhibitor maintenance therapy for advanced EC
• Long-term efficacy and safety findings from the Phase III KEYNOTE-775 trial comparing lenvatinib/pembrolizumab to chemotherapy for patients with advanced EC previously treated with a platinum-based regimen
• Strategies to safely and effectively utilize pembrolizumab/lenvatinib; approaches to dosing and side-effect prevention and management
• Current role of pembrolizumab/lenvatinib in EC management algorithms

MODULE 3: Promising Agents Under Investigation for EC

• Biological rationale for the evaluation of TROP2-directed ADCs for advanced EC
• Preliminary efficacy and safety findings reported with sacituzumab govitecan for patients with pretreated advanced EC
• Design, eligibility criteria and primary and secondary endpoints of the ongoing Phase III ASCENT-GYN-01 trial evaluating sacituzumab govitecan versus treatment of physician’s choice for patients with EC who have experienced disease relapse after platinum-based chemotherapy and immunotherapy
• Early efficacy outcomes documented with other TROP2-directed ADCs, such as datopotamab deruxtecan, sacituzumab tirumotecan
• Other ongoing Phase III trials evaluating TROP2-directed ADCs
• Mechanism of action of selinexor and biological rationale for its evaluation in EC, particularly for TP53 wild-type disease
• Updated efficacy and safety findings with and ongoing Phase III evaluation of selinexor as maintenance therapy after first-line chemotherapy for patients with TP53 wild-type advanced or recurrent EC
• Other promising agents and strategies under investigation for advanced EC

Target Audience
This activity is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Assess the clinical and biological characteristics of the various histologic subtypes and molecular subgroups of endometrial cancer (EC), and consider the implications for prognosis, biomarker evaluation and therapeutic decision-making.
• Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with microsatellite instability-high/mismatch repair (MMR)-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
• Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC.
• Review available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC to receive this novel approach.
• Recognize the biological rationale for the evaluation of trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugates for patients with EC, and consider available research findings with and potential of these agents.
• Recognize adverse events associated with available and investigational therapies used in the treatment of EC to educate patients and manage complications.
• Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided.

FACULTY
To be announced.

MODERATOR
To be announced.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Eisai Inc, Gilead Sciences Inc, GSK, Karyopharm Therapeutics, and Merck.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.